Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
A pivotal push from BeiGene
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Private US biotechs head for human trials
Halda, Accent and Vividion take more projects into phase 1.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
